Chronic obstructive pulmonary disease and cardiovascular diseases: a "vulnerable" relationship. Am J Respir Crit Care Med. 2013 Jan 1;187(1):2-4 Authors: Sin DD, Macnee W PMID: 23281347 [PubMed - in process] (Source: American Journal of Respiratory and Critical Care Medicine)

Authors: Toonkel RL, Hare JM, Matthay MA, Glassberg MK Abstract Idiopathic Pulmonary Fibrosis (IPF) is a progressive, debilitating, and fatal lung disease characterized by interstitial fibrosis with decreasing lung volumes and hypoxemic respiratory failure. The prognosis for patients with IPF is poor and the quest to find effective therapies has been unsuccessful. Despite several clinical trials over the past decade, there are no FDA approved treatments for patients with IPF and thus no standard of care. In terms of pathogenesis, IPF is characterized by alveolar epithelial cell injury and activation with interstitial inflammation, fibroblast proliferation with extracellular matrix collagen deposition, and loss of lung function. Because mesenchymal stem cells (MSCs) home to sites of...

CONCLUSION: Integration of biomarkers with lung nodule size has the potential to help guide the management of patients with indeterminate pulmonary nodules. PMID: 23306547 [PubMed - as supplied by publisher] (Source: American Journal of Respiratory and Critical Care Medicine)

The Elusive "Gold" Standard for Detecting Mycobacterium tuberculosis Infection. Am J Respir Crit Care Med. 2013 Jan 15;187(2):122-4 Authors: Mancuso JD, Bernardo J, Mazurek GH PMID: 23322793 [PubMed - in process] (Source: American Journal of Respiratory and Critical Care Medicine)